1. Home
  2. |Professionals
  3. |Jill Abrams

Jill Abrams

Senior Counsel
Senior Counsel
amlsbGFicmFtc0Bjcm93ZWxsLmNvbQ==
VCard
VCard

Areas of Focus

Overview

Jill Abrams is a senior counsel in Crowell & Moring’s Washington, D.C. office and a member of the firm’s Health Care Practice. She advises on managed care compliance and enforcement matters, with a focus on Medicare Advantage (MA) and Medicare Part D. Prior to joining Crowell, she spent over 20 years at the U.S. Department of Health and Human Services (HHS), where she took a key role in most of the significant enforcement matters regarding these programs. 

At HHS, Jill served as senior attorney in the Office of the General Counsel’s Centers for Medicare and Medicaid Services (CMS) Division, where she advised on fraud and abuse, enforcement, and other policy issues, working closely with the U.S. Department of Justice (DOJ) and the HHS Office of the Inspector General. Her extensive experience in this role and knowledge of agency personnel allows her to provide valuable support to managed care clients on regulatory and enforcement matters as well as appeals.

Jill’s experience includes advising on:

  • Government audits, including risk adjustment data validation (RADV) audits
  • Internal investigations
  • Disclosures to the government
  • Developing and implementing compliance plans
  • New and evolving regulations and guidance
  • Disputes with downstream service providers to MA plans
  • Medicare marketing rules
  • Compliance and enforcement actions, including sanctions, CMPs, and terminations
  • Administrative appeals processes relating to MA and Part D
  • General regulatory counseling regarding the prescription drug price negotiation program, particularly compliance and enforcement involving drug manufacturers
  • False Claims Act (FCA) cases involving MA and Part D

Career & Education

    • University of Michigan Law School, J.D., 1999
    • University of Pennsylvania, B.A., 1994
    • University of Michigan Law School, J.D., 1999
    • University of Pennsylvania, B.A., 1994

    • District of Columbia
    • District of Columbia

Jill 's Insights

Client Alert | 21 min read | 12.04.25

Highlights: CMS’s Proposed Rule for Medicare Part C & D (CY 2027 NPRM)

On November 26, 2025, the Centers for Medicare & Medicaid Services (CMS) published its Proposed Rule for the Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (the “CY 2027 NPRM” or “proposed rule”) for public comment. In addition to outlining prospective policy and technical changes to Medicare Advantage (Part C), the Medicare Prescription Drug Benefit (Part D), and Medicare Cost Plan regulations, the proposals showcase the government’s plans to make comprehensive updates in response to statutory changes—notably the Inflation Reduction Act of 2022 (IRA)—as well as feedback from interested parties, and current federal deregulatory priorities....

View All Insights

Recognition

  • Office of the General Counsel: Excellence of Service Group Award, Inflation Reduction Act Implementation and Legal Defense Team, 2024
  • Centers for Medicare and Medicaid Services Division: Program Impact Award, Risk Adjustment Data Validation Final Rule Team, 2023
  • Centers for Medicare and Medicaid Services Division: Secretary’s Award for Distinguished Service, Medicare Modernization Act Regulations Development Team, 2005

Jill 's Insights

Client Alert | 21 min read | 12.04.25

Highlights: CMS’s Proposed Rule for Medicare Part C & D (CY 2027 NPRM)

On November 26, 2025, the Centers for Medicare & Medicaid Services (CMS) published its Proposed Rule for the Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (the “CY 2027 NPRM” or “proposed rule”) for public comment. In addition to outlining prospective policy and technical changes to Medicare Advantage (Part C), the Medicare Prescription Drug Benefit (Part D), and Medicare Cost Plan regulations, the proposals showcase the government’s plans to make comprehensive updates in response to statutory changes—notably the Inflation Reduction Act of 2022 (IRA)—as well as feedback from interested parties, and current federal deregulatory priorities....

View All Insights

Practices

Industries

Jill 's Insights

Client Alert | 21 min read | 12.04.25

Highlights: CMS’s Proposed Rule for Medicare Part C & D (CY 2027 NPRM)

On November 26, 2025, the Centers for Medicare & Medicaid Services (CMS) published its Proposed Rule for the Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (the “CY 2027 NPRM” or “proposed rule”) for public comment. In addition to outlining prospective policy and technical changes to Medicare Advantage (Part C), the Medicare Prescription Drug Benefit (Part D), and Medicare Cost Plan regulations, the proposals showcase the government’s plans to make comprehensive updates in response to statutory changes—notably the Inflation Reduction Act of 2022 (IRA)—as well as feedback from interested parties, and current federal deregulatory priorities....

View All Insights